Former Johnson & Johnson scientists launch highly bioavailable CBD delivery system
NextEvo’s SmartSorb technology turns oil-soluble, hemp-derived CBD oils into water-dispersible emulsions while boosting CBD content.
A firm founded by former staff and scientists from companies like Johnson & Johnson, GlaxoSmithKline, and Schiff Nutrition is bringing a new delivery platform to market that boosts the bioavailability of hemp cannabidiol (CBD). According to the company, NextEvo (Conshohocken, PA), its SmartSorb technology not only turns oil-based CBD ingredients into water-soluble ingredients but also enables a higher load of active CBD ingredient.
“SmartSorb turns premium, hemp-derived CBD, which is usually oil soluble, into a water soluble–like (water-dispersible) emulsion and delivers the equivalent of four times the amount of CBD in oil-based formulations,” said the company in a press release. It continued: “While many products on the market claim water solubility and bioavailability of ingredients, NextEvo has demonstrated the superiority of its SmartSorb technology through evidence-based trials and will conduct additional trials this year.”
“The CBD market has been growing at a rapid rate since the passage of the 2018 Farm Bill, but most CBD products currently sold on shelves don’t offer data that proves CBD bioavailability, delivery, or potential effects,” said John McDonagh, NextEvo Naturals CEO and president, in a press release. “We aim to be pioneers in changing that and utilize our team of experts, many of whom have led decades of research and development on compound delivery at prestigious healthcare leaders such as Johnson & Johnson and GlaxoSmithKline, to provide consumers with the best, evidence-backed products on the market.”
The company is now offering three products featuring SmartSorb: Premium Pure CBD (10-mg, high-absorption CBD capsules), Premium Pure CBD Extra Strength (15-mg CBD capsules, also available in chewable tablets), and Triple Action Sleep (which combines 5 mg of Premium Pure CBD with controlled-release melatonin).
To develop, pre-launch, and commercialize SmartSorb, NextEvo used proceeds from a $15 million investment round led by Intrinsic Capital Partners. The company says SmartSorb allows for rapid CBD absorption and improved delivery.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
